Abstract:<p>Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.</p>

Strategy to Regulate the Stability and Reduction Rate of Oxaliplatin-Based Pt(IV) Complexes: Cocrystallization

Slow-Release Drug–Drug Cocrystals of Oxaliplatin with Flavonoids: Delaying Hydrolysis and Reducing Toxicity

Rapid DNA interstrand cross-linking of Pt(IV) compound

Pt( iv ) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Cis-[Pt(ii) (1R,2r-Dach)(3-acetoxy-1,1-cyclobutanedicarboxylato)], a Water-Soluble, Oxalate-Free and Stable Analogue of Oxaliplatin: Synthesis, Characterization, and Biological Evaluations.

Stability studies on 12-(5′-8′- hydroxyquinolinic)methylene-1,4,7,10-tetraazacyclo tridecane-11,13-dione, 5-substituted 1,10-phenanthroline-copper(II) with Cu2+ or Co2+ binuclear mixed-coordinated systems

Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety

Self-controlled Release of Oxaliplatin Prodrug from D-Α-tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) Functionalized Mesoporous Silica Nanoparticles for Cancer Therapy

Ligand substitution reactions afford oxaliplatin-based platinum( iv ) complexes bearing axial alkoxido ligands

Hyaluronic Acid Oligosaccharide-Modified Zeolitic Imidazolate Framework-8 Nanoparticles Loaded with Oxaliplatin As a Targeted Drug-Delivery System for Colorectal Cancer Therapy

Molecular-scale Drug Delivery Systems Loaded with Oxaliplatin for Supramolecular Chemotherapy

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Ph and Reduction Dual-Responsive Bi-Drugs Conjugated Dextran Assemblies for Combination Chemotherapy and in Vitro Evaluation

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Reversal of Cisplatin Resistance in Human Gastric Cancer Cells by a Wogonin-Conjugated Pt(IV) Prodrug Via Attenuating Casein Kinase 2-Mediated Nuclear Factor-κB Pathways.

Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs

Oleanolic acid-NO donor-platinum(II) trihybrid molecules: Targeting cytotoxicity on hepatoma cells with combined action mode and good safety

A New Technique for Synthesis of Oxaliplatin

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity

Preparation, Characterisation And Antitumour Activity Of Beta-, Gamma- And Hp-Beta-Cyclodextrin Inclusion Complexes Of Oxaliplatin